Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more
Market Cap & Net Worth: Evogene (EVGN)
Evogene (NASDAQ:EVGN) has a market capitalization of $7.60 Million ($7.60 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29760 globally and #9843 in its home market, demonstrating a 14.01% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evogene's stock price $0.87 by its total outstanding shares 8718193 (8.72 Million).
Evogene Market Cap History: 2015 to 2026
Evogene's market capitalization history from 2015 to 2026. Data shows change from $701.81 Million to $7.60 Million (-35.43% CAGR).
Index Memberships
Evogene is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #769 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2459 of 3165 |
Weight: Evogene's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Evogene Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evogene's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.92x
Evogene's market cap is 1.92 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $701.81 Million | $11.13 Million | -$17.21 Million | 63.06x | N/A |
| 2016 | $444.63 Million | $6.54 Million | -$19.59 Million | 67.99x | N/A |
| 2017 | $267.65 Million | $3.38 Million | -$20.84 Million | 79.16x | N/A |
| 2018 | $172.62 Million | $1.75 Million | -$20.76 Million | 98.81x | N/A |
| 2019 | $132.52 Million | $753.00K | -$18.11 Million | 175.98x | N/A |
| 2020 | $409.76 Million | $1.04 Million | -$23.37 Million | 394.00x | N/A |
| 2021 | $142.98 Million | $930.00K | -$27.79 Million | 153.74x | N/A |
| 2022 | $61.03 Million | $1.68 Million | -$26.64 Million | 36.43x | N/A |
| 2023 | $73.23 Million | $5.64 Million | -$23.88 Million | 12.98x | N/A |
| 2024 | $16.30 Million | $8.51 Million | -$16.48 Million | 1.92x | N/A |
Competitor Companies of EVGN by Market Capitalization
Companies near Evogene in the global market cap rankings as of March 18, 2026.
Key companies related to Evogene by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Evogene Historical Marketcap From 2015 to 2026
Between 2015 and today, Evogene's market cap moved from $701.81 Million to $ 7.60 Million, with a yearly change of -35.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.60 Million | -20.72% |
| 2025 | $9.59 Million | -41.18% |
| 2024 | $16.30 Million | -77.74% |
| 2023 | $73.23 Million | +20.00% |
| 2022 | $61.03 Million | -57.32% |
| 2021 | $142.98 Million | -65.11% |
| 2020 | $409.76 Million | +209.21% |
| 2019 | $132.52 Million | -23.23% |
| 2018 | $172.62 Million | -35.50% |
| 2017 | $267.65 Million | -39.80% |
| 2016 | $444.63 Million | -36.65% |
| 2015 | $701.81 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Evogene was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.60 Million USD |
| MoneyControl | $7.60 Million USD |
| MarketWatch | $7.60 Million USD |
| marketcap.company | $7.60 Million USD |
| Reuters | $7.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.